Abstract:Wensheng Lu, 1 JianFeng Wang, 2 YuanJing Zhang, 1 Ruixue Chang, 1 Jun Zhao 3 1 Department of Dermatology, The No. 1 Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, People's Republic of China; 2 Department of Dermatology, The No. 1 Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China; 3 Department of Dermatology, The Lu'an Hospital Affiliated to Anhui Medical University, Lu'an, Anhui, People's Republic of China Correspondence: Wensheng Lu; Jun Zhao, Email ; Introduction: This study observed the effectiveness of ustekinumab and reactivation risk of concurrent latent tuberculosis infection (LTBI) and inactive hepatitis B virus (HBV) infection in Chinese mainland psoriasis patients on ustekinumab treatment. Methods: This retrospective, multicenter, observational study was conducted in three centers in China. Adult patients with moderate to severe plaque psoriasis were treated with ustekinumab for 28 weeks. The effectiveness endpoint included 75% and 90% improvement in Psoriasis Area Severity Index (PASI75/90) response rate, percentage of PASI improvement, change of absolute PASI score and body surface area involvement (BSA) score, absolute PASI ≤ 1/3 and Physicians' Global Assessment (PGA)=0/1, as well as Dermatology life quality index (DLQI)=0/1 response rate at week 4, 16 and 28. Screening of tuberculosis and hepatitis were performed at baseline and week 28. Results: A total of 82 patients were enrolled between March 2021 and May 2023 and the number of patients combined with LTBI and inactive HBV infection was 20 and 21 respectively. The PASI75 and PASI90 response rate at week 28 was 95.1% and 81.7% respectively. The mean PASI score decreased from 14.93 ± 12.07 at baseline to 0.78 ± 1.86 at week 28, and the mean BSA score decreased from 21% ± 18% at baseline to 1% ± 2% at week 28 (both P< 0.001 compared with baseline). DLQI 0/1 response rate at week 28 was 73.2%. No reactivation of LTBI and inactive HBV infection and also no new-onset tuberculosis and hepatitis B occurred in patients without LTBI and inactive HBV infection at baseline. Conclusion: Ustekinumab demonstrated great effectiveness in Chinese plaque psoriasis patients and good safety in psoriasis concurrent with LTBI and inactive HBV infection under the real-world setting. Keywords: ustekinumab, plaque psoriasis, real-world effectiveness, LTBI, inactive HBV infection Psoriasis is a chronic, recurrent, inflammatory and systematic skin disease which affects around 0.47% of Chinese people and causes large impairments to the quality of life of patients; 89.1% of Chinese psoriasis patients suffer from mental health problems caused by psoriasis. 1,2 The most common subtype of psoriasis is plaque psoriasis (PsO), which accounts for 84.5% of Chinese psoriasis patients and is characterized by well demarcated, red and raised plaques covered by silvery scales. 3 In recent years, the improvements of anti-interleukin biologics included IL12/23i, IL-17Ai and IL-23i brought great improvement for the treatment of PsO. 4 However, the infection risk of biologics still requires special attention in patients combined with HBV and tuberculosis infection, especially in countries with high HBV and tuberculosis burden such as China. Nearly half of Chinese population are infected with mycobacterium tuberculosis and the infection rate ranking top 2 globally. 5 About 70 million people are chronic HBV infection patients in China. 6 With the high skin lesion clearance rate of new anti-interleukin biologics, more and more physicians pay attention to the quality of life of psoriasis patients. Several trials used patient-reported outcomes such as DLQI as an important endpoint to evaluate the impact of biologics on patients' quality of life. 7–9 Ustekinumab, a fully human anti-IL12/23 monoclonal antibody that binds to the P40 subunit shared by IL-12 and IL-23 therefore inhibits the downstream inflammatory signal pathway, is the first approved anti-interleukin biologic for the treatment of plaque psoriasis which was approved by FDA in 2009. 10 In 2017, ustekinumab was approved for the treatment of Chinese adult moderate to severe plaque psoriasis patients and in 2023 it was approved for the treatment of Chinese 6–17 year old pediatric plaque psoriasis patients weighing 60–100 kg. 7,11,12 Previous genome-wide association studies found that IL-12B and IL-23R are susceptibility genes of Chinese psoriasis patients. 13,14 A randomized, double-blind, placebo-controlled study also indicated that ustekinumab demonstrated great efficacy and -Abstract Truncated-

Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study

Expert Consensus on the Treat-to-target Strategy for Psoriasis with Biological Agents in China

Efficacy And Safety Of Ustekinumab In Chinese Patients With Moderate To Severe Plaque-Type Psoriasis: Results From A Phase 3 Clinical Trial (Lotus)

Indirect Regulation and Equilibrium of P35 and P40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment.

Anti-TNF- Αtreatment-Related Pathways and Biomarkers Revealed by Transcriptome Analysis in Chinese Psoriasis Patients

Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy

Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients

Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: 60-Week Results from a Phase 3 Study

25258 Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-severe Plaque Psoriasis: 12-Week Results from a Phase 3 Study

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

Ustekinumab improves health-related quality of life in Chinese patients with moderate-to-severe plaque psoriasis: results from the LOTUS trial and curative effect observation

Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study

14066 Pharmacokinetics, Safety and Efficacy of Ixekizumab in Chinese Patients with Plaque Psoriasis: Results from a Phase 1 Single- and Multiple-Dose Study

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Recombinant Human Tumor Necrosis Factor Receptor Type Ⅱ - IgG Fc Fusion Protein for the Treatment of Moderate to Severe Psoriasis Vulgaris:A Multicenter, Randomized, Parallel-Group, Controlled Clinical Trial

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study